By far the biggest of the takeover bids in recent times - the prospective buyout bid by Pfizer Inc for buyout of its rival Wyeth for a monstrously huge $60 billion - will likely come through!

Even with the tight credit markets, Pfizer will probably be able to secure funding for the whopping amount, largely because of the brand names of both the companies as well as their cash-rich balance sheets.

Pfizer expects $17-18 billion in cash flow from its 2008 operations. Moreover, the quarterly filing revealed the company's balance sheet consisting $26 billion in cash, cash equivalents and short-term investments; and $16.3 billion in short-term borrowings and long-term debt.

As per CNBC, for the deal that can be financed with a mix of cash and stock, Pfizer was seeking $25 billion in financing - a pretty bold move by the world's biggest drugmaker!

If the Pfizer acquisition of Madison, NewJersey-based Wyeth comes through, it will spell transformation for the company - the essentially pharmaceutical company will overnight turn into an extensively-diversified health care giant! Pfizer will stand to gain from Wyeth's dominating presence and revenue in biotech drugs, consumer health products and vaccines like the popular pneumococcal vaccine Prevnar.

Saying that the reports of the proposed deal were not surprising, Credit Suisse analyst Catherine Arnold said: "Such an acquisition makes strategic and financial sense. This deal would instantly make (Pfizer) a top-tier biologics player."